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Abstract
Background: HIV prevention research in resource-limited countries is associated with a variety
of ethical dilemmas. Key amongst these is the question of what constitutes an appropriate standard
of health care (SoC) for participants in HIV prevention trials. This paper describes a community-
focused approach to develop a locally-appropriate SoC in the context of a phase III vaginal
microbicide trial in Mwanza City, northwest Tanzania.
Methods: A mobile community-based sexual and reproductive health service for women working
as informal food vendors or in traditional and modern bars, restaurants, hotels and guesthouses
has been established in 10 city wards. Wards were divided into geographical clusters and
community representatives elected at cluster and ward level. A city-level Community Advisory
Committee (CAC) with representatives from each ward has been established. Workshops and
community meetings at ward and city-level have explored project-related concerns using tools
adapted from participatory learning and action techniques e.g. chapati diagrams, pair-wise ranking.
Secondary stakeholders representing local public-sector and non-governmental health and social
care providers have formed a trial Stakeholders' Advisory Group (SAG), which includes two CAC
representatives.
Results: Key recommendations from participatory community workshops, CAC and SAG
meetings conducted in the first year of the trial relate to the quality and range of clinic services
provided at study clinics as well as broader standard of care issues. Recommendations have
included streamlining clinic services to reduce waiting times, expanding services to include the
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children and spouses of participants and providing care for common local conditions such as
malaria. Participants, community representatives and stakeholders felt there was an ethical
obligation to ensure effective access to antiretroviral drugs and to provide supportive community-
based care for women identified as HIV positive during the trial. This obligation includes ensuring
sustainable, post-trial access to these services. Post-trial access to an effective vaginal microbicide
was also felt to be a moral imperative.
Conclusion: Participatory methodologies enabled effective partnerships between researchers,
participant representatives and community stakeholders to be developed and facilitated local
dialogue and consensus on what constitutes a locally-appropriate standard of care in the context
of a vaginal microbicide trial in this setting.
Trial registration: Current Controlled Trials ISRCTN64716212
Background
There has been considerable debate over the last 10-15
years as to what constitutes an appropriate standard of
health care (SoC) in the context of clinical trials con-
ducted in resource-poor countries [1-3].
HIV prevention trials present a number of unique ethical
dilemmas for researchers [4-12]. In many developed and
developing countries, such trials are feasible only among
vulnerable sub-populations at high-risk of HIV infection
and sexually transmitted infections (STIs)[13,14], where
poverty, stigma and social exclusion are significant barri-
ers to local health care access and decisions regarding SoC
provision are therefore paramount [15-18].
There is currently no international consensus on research-
ers' responsibility to meet the health needs of clinical trial
participants or their obligations to the wider community
from which participants are drawn. In 2000, the World
Medical Association (WMA) revised the Declaration of
Helsinki, stating in paragraph 29 that the "best current
prophylactic, diagnostic and therapeutic methods" i.e. the
highest possible SoC should be made available to people
participating in clinical research [19]. Guidelines pro-
duced subsequently by the UK Nuffield Council on
Bioethics [20], the US National Bioethics Advisory Com-
mission (NBAC) [21], the Council for International
Organization of Medical Sciences (CIOMS) [22] and
UNAIDS [23] contradict this construct of SoC however
and propose that it is ethically justifiable, under certain
conditions, to provide less than the worldwide best stand-
ard. For example, both the NBAC and CIOMS guidelines
recommend that clinical trial participants be given "estab-
lished effective" therapy as a minimum whilst the Nuff-
ield Council on Bioethics recommends:
"where it is not appropriate to offer a universal [i.e. 'world-
wide best'] standard of care, the minimum standard of
care that should be offered to the control group is the best
intervention available for that disease as part of the
national public health system".
More recently, international debate has shifted from these
narrow definitions of SoC, in which researchers' obliga-
tion to subjects randomised to the placebo or control
arms of HIV prevention trials are a particular focus, to a
broader conceptualisation of SoC based on the principles
of equity, social justice and beneficence that consider the
overall health needs of trial participants and the commu-
nity within which research is conducted [16,24]. This
approach is supported by recent community-based
research in East and Southern Africa, India and the United
States, which has highlighted the pivotal role of commu-
nity participation and the importance of open, effective
dialogue between researchers and community stakehold-
ers in the on-going SoC debate [12,17,18,25].
Mwanza is one of six centres in sub-Saharan Africa partic-
ipating in the Microbicides Development Programme
(MDP), an international partnership for the development
of vaginal microbicides for HIV prevention, funded by the
UK Department for International Development and Med-
ical Research Council (MRC)[26]. A feasibility study [27]
was carried out among an occupational cohort of women
at increased risk of HIV infection and STIs in ten adminis-
trative wards in Mwanza City, northwest Tanzania
between July 2002 and March 2005 in preparation for the
on-going MDP301 randomized placebo-controlled effi-
cacy and safety trial of the candidate vaginal microbicide
PRO2000/5 Gel (Indevus Pharmaceuticals, USA), which
started in November 2005. Women working in food and
recreational facilities, including modern bars, traditional
bars (known as vilabu or pombe shops in Tanzania), res-
taurants, hotels, guesthouses, groceries and as informal
food vendors (known locally as mamalishe), are eligible to
participate. Research conducted at a number of sites in
Tanzania suggests that some women in this occupational
group periodically supplement their income through
BMC Medical Ethics 2009, 10:17 http://www.biomedcentral.com/1472-6939/10/17
Page 3 of 12
(page number not for citation purposes)
transactional sex [28,29] and are hence at increased risk of
STIs and HIV infection [27,30-32]
In this paper we describe how a locally-appropriate SoC
package was developed by researchers, study participants
and community stakeholders in the context of the
MDP301 vaginal microbicide trial in Mwanza; present
case studies to illustrate some of the ethical issues and
dilemmas encountered during implementation; and criti-
cally appraise whether the strategies adopted have been
successful in this setting.
Methods
Study population
The design of the microbicide trial feasibility study in
Mwanza and the baseline socio-demographic, behav-
ioural and biomedical characteristics of study participants
have previously been described [27]. In brief, following
participatory community mapping to identify eligible
food and recreational facilities in ten administrative wards
in Mwanza City, a community-based clinic was estab-
lished in a guesthouse in each ward by October 2002.
Study clinics provided free sexual and reproductive health
services to participants including voluntary HIV counsel-
ling and testing; STI syndromic management; family plan-
ning advice and contraceptive methods; and health
education. Participants found to be HIV positive were
referred to a specialist local public health provider for
clinical assessment and care which included antiretroviral
provision if appropriate. In addition, a system of referral
to a network of local non-governmental and community-
based organizations (NGOs and CBOs) providing care
and support for participants and their families living with
HIV and AIDS was established. Participants with general
medical or gynaecological problems were referred to
established local care providers for further clinical assess-
ment. A total of 1573 women were enrolled and followed
up at three-monthly intervals for a maximum of two years.
The feasibility study ended in March 2005 with the com-
pletion of a small pilot study, conducted among 59 partic-
ipants, to investigate the acceptability of HPTN035
Placebo Gel in this study population and the feasibility
and acceptability of proposed clinical trial procedures
[33].
Following the successful completion of the feasibility and
pilot studies in Mwanza, the MDP301 efficacy and safety
trial started in November 2005. A total of 1146 HIV sero-
negative subjects have been enrolled into the main trial in
Mwanza, with follow-up completed in mid-2009. Trial
participants, and women who participated in the feasibil-
ity and/or pilot studies, are all eligible to receive free sex-
ual and reproductive health services through the
community-based study clinics and have access to ancil-
lary care by referral (Table 1).
Community liaison
During the Mwanza feasibility study, a community liaison
system (CLS) was established, based on 78 geographical
clusters of facilities in ten city wards [34], and has used
participatory research tools to facilitate open dialogue and
partnership working practices between researchers, study
participants and community representatives [25]. The def-
inition of 'community' adopted in Mwanza was conceived
and articulated by study participants who perceived them-
selves not only as part of an occupational group, but as a
discrete community with shared social ties, perspectives
and experiences within a defined geographical location
[34,35]. Cluster, ward and city-level representatives have
been elected in a process facilitated by the site Commu-
nity Liaison Officer (CLO) and a Community Advisory
Committee (CAC) established. In community workshops
at ward and city level, listing, ranking, diagramming and
other techniques were used to capture and prioritise
project-related concerns, including issues related to the
scope and quality of health services provided by study
clinics to participants, their families and the broader com-
munity [25]. With the start of the MDP301 trial in
Mwanza, the CLS has been consolidated and expanded
with new facility clusters and associated representatives
developed in close consultation with the community. Par-
ticipatory community workshops have continued every 4-
6 months during the main trial in order to monitor com-
munity perceptions of the study and in particular, to
ensure that decisions about clinical services provided by
or through the project are taken in consultation with 'pri-
mary' stakeholders i.e. potential and actual study partici-
pants.
Stakeholders Advisory Group
During the feasibility study, researchers established links
at all levels with key local public-sector, non-governmen-
tal and community-based stakeholders providing health
and social support in Mwanza ('secondary stakeholders').
Senior staff provided six-monthly progress updates to the
Mwanza City HIV/AIDS Management Committee, which
provided a useful forum in which to discuss a broad range
of issues with representatives from the local public and
non-governmental sector, including SoC and the ethics of
trial participation in vulnerable communities. These
meetings led to the formation of a project-specific Stake-
holders Advisory Group (SAG) in June 2006, designed to
complement the guidance and advice provided through
the CAC. During the MDP301 trial, the SAG has contin-
ued to meet routinely every 4-6 months to review progress
and to make suggestions as to how clinical care for trial
participants could be consolidated, improved or delivered
in alternative ways. The SAG now includes representatives
from the City health department, local public health pro-
viders, non-governmental and community-based organi-
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sations (NGOs and CBOs) active in HIV care and support
and two representatives from the CAC.
Ethical approval
Ethical clearance for the feasibility study and the MDP301
clinical trial in Mwanza was obtained from the National
Medical Research Coordinating Committee in Tanzania
and the Ethics Committee of the London School of
Hygiene and Tropical Medicine UK. Written informed
consent (signature or witnessed thumbprint) is obtained
from all participants prior to enrolment.
A SoC statement, encapsulating the clinical care package
described in Table 1 above, was ratified by the Ethics
Committees in Tanzania and UK and by the Mwanza
Community (CAC) and Stakeholders (SAG) Advisory
Groups prior to the start of the main trial.
Results
Community workshops and CAC meetings
Community workshops in Mbugani, Pamba, Igoma and
Nyamanoro wards conducted between October and
December 2006 highlighted a variety of issues related to
Table 1: MDP301 Mwanza clinical care package
Eligibility criteria: summary of those eligible to receive clinical care package provided through study clinics and referral services
All current MDP301 trial participants (scheduled clinical review as per trial protocol plus drop-in visits at any time)
All women who attended a screening visit for the MDP301 trial but were subsequently excluded or decided not to enrol (drop-in visits at any time)
All women who participated in the MDP Mwanza feasibility or pilot study (drop in visits at any time)
Male sexual partners of any of the above women were eligible for STI referral services
Summary of care provided in study clinics and via referral services
Management of STIs/RTIs
Syndromic STI management (based on national guidelines produced by the MoH in Tanzania[36]) supplemented by vaginal pH for bacterial vaginosis 
and collection of genital specimens and venepuncture according to trial Standard Operating Procedures (SOPs)
Clinical management subsequently adjusted as appropriate at next clinic visit based on laboratory test results (N. gonorrhoeae, C. trachomatis, T. 
vaginalis, Herpes simplex type-2, syphilis, bacterial vaginosis)
Sexual partners are advised to attend a designated collaborating local service provider for free STI care 
(women provided with referral slips; anonymised notification sent to a designated local STI care service provider)
HIV diagnosis and care
Voluntary HIV testing and counselling (VCT): same-day service using parallel rapid diagnostic tests supplemented by laboratory-based ELISA 
confirmation as appropriate and as specified in site SOPs
Women found to be HIV seropositive at the MDP301 screening visit, who seroconvert during the trial or who were diagnosed as HIV seropositive 
during the feasibility study are referred to a local collaborating specialist centre providing free HIV clinical care and support, including CD4 count 
estimation, diagnosis and management of tuberculosis and opportunistic infections, antiretroviral drug therapy and clinical monitoring
Counselling and support for women found to be HIV positive is provided at study clinics and via a local referral network established with CBOs and 
NGOs in Mwanza through the community liaison system. Free specialist support for women living with HIV is also available through this network 
e.g. legal advice regarding land and housing issues and related permanency arrangements
Family planning
Free counselling and advice regarding different forms of family planning are provided in study clinics, which also provide condoms, combined oral 
contraceptives and Depo-Provera injections as appropriate
Women requesting tubal ligation or intrauterine contraceptive devices (IUCD) are referred to local designated service providers
Gynaecology, general medical and child health services
General medical and genital examinations are conducted in all subjects at the MDP301 screening visit. Genital examination is subsequently 
scheduled at three-monthly intervals in the MDP301 trial protocol. General and genital examinations are also available as indicated at any time
Women found to have a gynaecological abnormality (e.g. suspected carcinoma of the cervix identified macroscopically on speculum examination) 
are referred to a designated specialist who provides expedited care on a private patient basis. Referral costs are routinely met by the study. 
Summary medical reports are provided to the study team for filing in patient clinical record folders
Women found to have a general medical condition (e.g. hypertension, diabetes) are referred to one of several local physicians. Referral costs are 
met by the study as required
Participants requesting services or advice for their children (e.g. for childhood fever or other medical conditions) are advised to attend free local 
child health clinics for assessment and clinical management and are not treated for malaria or other conditions at MDP Mwanza study clinics
BMC Medical Ethics 2009, 10:17 http://www.biomedcentral.com/1472-6939/10/17
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the scope and range of clinical services provided during
the first year of the MDP301 trial in Mwanza that were fur-
ther investigated during two participatory CAC meetings
conducted in January and February 2007. Listing, ranking,
diagramming and pairwise matrices were used (Figure 1)
to establish a list of priority concerns, many of which were
similar to those highlighted during workshops held as
part of the earlier feasibility study [25] (Table 2). For
example, the change from metal vaginal specula in the
feasibility study to single-use plastic instruments in the
main trial has been associated with a reduction in
rumours and concerns about the safety of genital exami-
nation associated with perceptions about the cleanliness
of re-useable instruments. Blood taking remained a con-
cern in the first year of the trial but community percep-
tions that blood might be collected and sold for witchcraft
purposes were less common, following a variety of initia-
tives introduced during the feasibility study [25].
Priority concerns during both the feasibility study and the
main trial were primarily related to immediate issues of
current clinical service provision and the need to address
timeliness, efficiency and certain specific procedural mat-
ters (e.g. reimbursement levels; venepuncture) rather than
broader standard of care issues. Requests to broaden the
scope of services provided, in order that the children and
spouses of participants could receive treatment at study
clinics (rather than by referral), were raised in the feasibil-
ity study and the main trial. Access to care and support
services for women living with HIV and AIDS, including
antiretroviral therapy, was raised during the feasibility
study workshops but appeared of less concern in the main
trial, when specialist referral services had already been
established for some time. Concerns about ensuring post-
trial access to an effective microbicide gel were expressed
only in the later series of workshops.
Stakeholders Advisory Group recommendations
The SAG has considered SoC issues since its inception and
in contrast to the community group, has focussed prima-
rily on broader ethical issues related to clinical service pro-
vision for study participants, their families and the wider
community (Figure 2). Stakeholders felt that to provide
more than the best care available locally or to attempt to
provide the 'worldwide best care' to trial participants
would be coercive and unethical in this setting since it
would not be possible to extend such services beyond
those participating in the trial or to sustain such levels of
care following trial cessation. In order to support local
health systems and human resource capacity develop-
ment, researchers were strongly advised to continue work-
ing within existing structures and to avoid setting up
parallel systems wherever possible. Stakeholders also
stressed concerns that client referrals from research clinics
could risk stretching already overburdened local health
services; and the importance of ensuring appropriate
resource inputs to offset such risks. The SAG also debated
concerns raised by the CAC and emphasised to the
research team the critical importance of maintaining effec-
tive community engagement in the management and
implementation of the trial in order to ensure that study
health services continue to be delivered in a locally-appro-
priate, acceptable and effective manner.
Issues and constraints in implementation
Having agreed the guiding principles for a locally-appro-
priate SoC package for study participants through consul-
tation with the CAC and SAG, the research team
encountered considerable difficulties successfully imple-
menting the clinical care package (Table 1) due to a com-
bination of logistical and socio-cultural factors, in
response to which a variety of corrective actions have been
taken (Table 3).
Despite these significant contextual factors, progress has
been made in meeting the four SAG recommendations.
The project has established collaborative agreements with
local service providers, which have secured funding
through government and external donors in the medium-
to-long term ensuring treatment and care services for
women living with HIV and AIDS can be sustained
beyond the end of the MDP301 trial in Mwanza. To
ensure post-trial access to a successful vaginal microbi-
cide, a register of trial participants is being collated that
will facilitate community tracing and subject enrolment
into future named-client phase IV trials. Referral services
have been established for sexual partners of study partici-
This figure is a photograph titled Using seeds to rank priori-tiesFigure 1
This figure is a photograph titled Using seeds to rank 
priorities.
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Table 2: List of key community concerns related to participation in the Mwanza feasibility study and MDP301 trial
Feasibility study MDP301 clinical trial
Issue 
(ranked in order of priority)
Comments by workshop 
participants (Sep 03 -- Mar 04)
Issue 
(ranked in order of priority)
Comments by workshop 
participants (Oct 06 -- Feb 07)
1. Blood taking 'why do you take so much blood every 
time?'
1. Allowances/reimbursal for 
participation
'life is becoming expensive and 
allowances are not enough -- why can't 
they be raised?'
'blood might fall into the wrong hands 
and be sold for witchcraft purposes'
'some of us have not received project 
T-shirts but others have already got 
theirs'
'we are supposed to get a soda and a 
snack when we arrive at the clinic but 
sometimes we are not given'
2. Allowances 'we are losing money when we come to 
clinic'
2. Range and quality of services 
provided
'staff sometimes don't listen as much 
as they could'
'clinics start late and are taking too 
long -- we spend the whole day there'
'we want to bring our children when 
they are sick'
'why can't you treat simple things like 
malaria?'
'are the lab tests trustworthy? Why are 
[HIV] tests not in little envelopes like 
before?
'why are some lab results not available 
when we come back to clinic?'
'what will happen once I finish [the 
trial] -- can I still get service at the 
study clinic?'
3. Speculum examinations 'how do we know the speculum is safe 
[clean]?'
3. Blood taking 'they are taking too much blood -- 
every time two bottles'
'after the blood test my heart was 
irregular for one week'
'one time after blood was taken I had 
pain in my arm for three days'
4. Range and quality of clinical 
services provided
'why can't we bring our children to the 
clinic when they are sick?'
4. Stigma 'people think that the bags [given to 
all participants at screening] used to 
collect gel must be for ARVs and that 
we must be positive'
'you should treat malaria and fever in 
children'
'the community is doubting that all 
those who join the project are HIV 
negative... we guess at least 40% 
should be positive'
'our men don't like to go to hospital 
[for STI treatment] - why can't we 
bring them to the clinic'
'sometimes we wait a long time to be 
seen'
'some tests take a long time to come 
back'
'I went [to another clinic] and got my 
result straight away after I had already 
waited a long time for my result from 
your clinic'
'how can you help me if I am/become 
HIV positive?'
5. Stigma and confidentiality 'people think that clinics are only for 
people who are HIV positive'
5. Issues related to study gel 'the gel increases wetness... makes 
men think there is some abnormality'
'my photograph might appear in the 
newspaper with my HIV result'
'the project needs to provide 
information to men... to educate them 
about gel'
'what will happen if gel is effective; will 
study volunteers get a supply?'
BMC Medical Ethics 2009, 10:17 http://www.biomedcentral.com/1472-6939/10/17
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pants and procedures instituted to monitor STI service
uptake and to consolidate partnership working with des-
ignated specialist providers in Mwanza, but there has been
less success in child health services (Table 3). Finally, the
project has made a commitment to provide services to
women working in food and recreational facilities in
Mwanza, irrespective of whether they are currently trial
participants, but does ask they have at least attended a
trial screening visit or been involved in the earlier feasibil-
ity or pilot studies.
Case studies
Another area in which the research team, community rep-
resentatives and stakeholders experienced difficulties was
in trying to decide where researchers' responsibility and
obligation to individual participants ended. The follow-
ing case study illustrates some of the ethical dilemmas
faced.
Case study: Acute psychosis and multiple vitamin deficiencies 
secondary to alcoholism
Researchers involved in the management of this case (Fig-
ure 3) felt that they had a clear duty of care to this partic-
ipant and that it was appropriate to use whatever project
resources were required to avert a life threatening situa-
tion. Ethically and morally we believe it would be difficult
to argue against this position. There was, however, some
debate within the research team as to whether our actions
could be viewed as inappropriate in the context of our
working definition of SoC based on access to the best
locally-available care, since the level of assistance pro-
vided was clearly in excess of that available to members of
the community outside the study population i.e. women
who were not working in eligible food or recreational
facilities in Mwanza. Having become involved in this
patient's care, it was also unclear at what point and how
we would decide whether or not to continue our assist-
ance, including financial support. For example, would it
still be appropriate for the project to pay for the costs of
referral to a regional medical centre (e.g. in Dar es Salaam
or Nairobi) should the patient's condition indicate that
this was necessary? Finally, some members of the team
were concerned that our actions could be misunderstood
in the community as being part of some sort of 'cover up'
to remove a woman experiencing severe side effects due to
her participation in the trial from further public scrutiny.
Consultation with community representatives and mem-
bers of the CAC and SAG subsequent to these events
revealed that the opposite was in fact the case: the prevail-
ing view in the community was that the project 'truly
cared about the women' participating in the trial and was
prepared to go to great lengths to assist them should they
encounter problems, even if these problems appeared
unrelated to trial participation.
Key recommendations of the MDP Mwanza Stakeholders Advisory GroupFigure 2
Key recommendations of the MDP Mwanza Stakeholders Advisory Group.
Responsibility to participants found to be HIV positive 
The research team has an ethical obligation to ensure that participants identified as HIV positive during the trial 
(either at screening or during follow-up) have effective access to the best services locally available including 
antiretroviral drugs and community-based care and support 
This obligation includes sustainable, post-trial access to these services
Responsibility with regard to a successful trial outcome 
Post-trial access to study product, if confirmed to be a safe and effective vaginal microbicide for HIV prevention, 
is a moral imperative
Responsibility to family members and children 
Researchers have a moral obligation to the families of study participants and should ensure as a minimum that the 
children and spouses of trial subjects are able to access appropriate local health services as required 
Responsibility to the community 
Wherever possible, researchers should provide the same SoC to members of the community from which study 
participants are drawn; in this case, all women working in food and recreational facilities in Mwanza City[34]
BMC Medical Ethics 2009, 10:17 http://www.biomedcentral.com/1472-6939/10/17
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Case study: Vaginal bleeding due to ectopic pregnancy
In another example, a woman with heavy vaginal bleed-
ing received specialist medical care and confirmation of a
provisional diagnosis of ectopic pregnancy within hours
of presentation at an MDP Mwanza trial clinic following
the urgent intervention of the research team. Researchers
again felt they had a clear moral obligation to this partic-
ipant and that it was appropriate to mobilise all resources
necessary (including staff time; project vehicles; specialist
referral, diagnostic, treatment and in-patient costs) to
Table 3: Issues and constraints to SoC package implementation
Service area and key issues Comments/Action taken
STI services for trial participants
Many trial participants do not receive the results of laboratory STI tests 
at their next scheduled visit
Some participants do not receive appropriate and timely additional 
treatment as indicated by their STI laboratory test results
Team meetings involving clinic and data management staff suggest these 
issues arose due to a combination of: difficulty tracing participants in the 
community to ask them to return for further treatment; difficulty 
ensuring continuity of care between visits due to high clinic through-put 
and multiple clinical staff (participants not assigned designated clinician); 
and inadequate systems and procedures to flag new test results (so that 
even when participants did return to clinic and STI test results were 
present in their study folder, appropriate treatment was not always 
given)
Systems for reporting STI tests were reviewed and modified Feb 08 to 
shorten turnaround time between testing and release of results to clinic
Reporting system modified to expedite the printing of all positive 
laboratory results and their prompt release to clinicians resulting in 
targeted community follow-up e.g. participants requiring additional 
treatment following initial syndromic-based STI management
Clinical tools developed to facilitate continuity of care training of 
clinicians modified to emphasize the importance of full review and 
continuity of care at each clinical visit
STI services for sexual partners
Trial participants complained that although they are being treated for 
STIs at study clinics they are at risk of re-infection because their sexual 
partners refuse to attend STI referral services
A review of referral service utilisation in Jan07 (based on an internal 
review of trial records and referral centre notification slips) indicated 
poor uptake by male sexual partners (< 30%)
Trial participants have continued to request that sexual partners receive 
treatment in study clinics rather than by referral
An internal review conducted in Jan 2007 concluded that systems for 
monitoring and evaluating service uptake be strengthened; that staff at 
the referral centre receive regular updates on the trial and training in 
relevant trial procedures (e.g. adverse event reporting in men); and that 
a greater focus be placed on male participation and support for the trial 
through community outreach activities. Despite implementing these 
initiatives, estimated service uptake remained < 30% in the year to Jul 
2008.
The issue of treating partners at study clinics has been explored several 
times in CAC and SAG meetings with the consensus view that study 
clinics have been established as 'a service for women provided by 
women' and that treating men at the same clinics would impact 
negatively on women's experience of clinic attendance and the trial.
Care and support for women living with HIV
A review of referral service utilisation in Jan07 (based on an internal 
review of trial records and referral centre notification slips) indicated 
poor uptake among women referred to the local collaborating specialist 
provider (< 30%)
During an internal review in Jan07, clinic staff were advised to emphasise 
the positive aspects of referral and to reaffirm that antiretroviral therapy 
can produce dramatic improvements in health and quality of life, even 
among those who present relatively late. Additional counselling and 
support were also offered to facilitate uptake but despite these 
measures, estimated service uptake remained < 30% in mid-2008.
Informal discussions with community representatives at workshops and 
CAC meetings have highlighted a number of potential constraints to 
service uptake, including stigma, travel and opportunity costs. These 
issues are being investigated in the Barriers Study that will inform local 
and national policy on ART access among vulnerable at-risk groups.
Gynaecology, general medical and child health 
All women with suspected cervical carcinoma and/or other 
gynaecological abnormalities on speculum examination have to date 
received specialist care in Mwanza
It has not been possible to track general medical and child health service 
uptake.
Trial participants have continued to request that children receive 
treatment in study clinics rather than by referral
A new Breast and Cervical Cancer Screening Clinic is being established 
at a tertiary care hospital in Mwanza in 2009.
Plans to implement visual inspection with acetic acid (VIA) in Dar es 
Salaam and Mwanza are on-going (K Shapiro, personal communication)
Better systems for tracking service uptake following referral are 
required in future clinical trials in Mwanza.
CAC and SAG meetings have discussed service provision for children 
periodically during the trial but on each occasion have accepted that a 
combination of logistical, funding, human resource, sustainability and 
other issues make it difficult for the MDP301 Mwanza trial team to 
provide child health services directly via study clinics. All parties have 
agreed that this issue be carefully assessed in future trial design.
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ensure access to the best possible care available locally,
even if this would have been impossible for her were she
not enrolled in the MDP301 trial.
Discussion
Participatory methodologies enabled effective partner-
ships between researchers, participant representatives and
community stakeholders to be developed during a vaginal
microbicide trial in Mwanza, Tanzania and facilitated
open dialogue and consensus on what constitutes an
appropriate standard of clinical care in this setting. By
actively seeking input from a combination of primary and
secondary stakeholders we were able to capture a broad
range of information from the practical and highly-spe-
cific (advising how study clinics might be more effectively
and appropriately implemented) to the conceptual
(researchers' moral and ethical obligations to trial partici-
pants, their families and the broader community).
The Mwanza experience reflects that of researchers and
ethics committees in other resource-limited settings where
locally-available levels of health care have been taken into
account when determining what constitutes appropriate
SoC rather than attempting to provide the highest possi-
ble SoC as advocated in the Declaration of Helsinki [1,2].
For example, a recent systematic review of 73 clinical trials
of HIV prevention and treatment (n = 34); malaria pre-
vention (n = 29); and tuberculosis treatment (n = 13), all
conducted in sub-Saharan Africa, found that only 16%
provided therapy consistent with the 'best current' stand-
ards of clinical care based on internationally agreed guide-
lines, such as those produced by the International AIDS
Society or the World Health Organization [15].
Our approach closely follows that advocated by Shapiro
and Benatar, who describe a seven step framework (Figure
4) to guide improved standards of care, based upon the
core principles of equity, social justice and beneficence
[16].
How well does our research measure up to this frame-
work? The MDP301 Trial in Mwanza has been conducted
in a specific occupational group within a defined geo-
graphical area among women vulnerable to HIV/STI infec-
tion, social harm and stigmatisation[25,27]. By actively
involving women who consider themselves part of a com-
munity defined by occupation, geography and research
participation; by establishing collaborative partnerships
within the broader local community; by defining key ele-
ments of SoC; and by providing evidence-based interven-
tions (such as STI syndromic management; VCT and risk
reduction counselling) a locally-appropriate care package
was developed. The feasibility study, pilot study and clin-
ical trial have all been implemented through community-
based clinics allowing women who are typically marginal-
ised within the broader Mwanza community, and who
thereby find it difficult to access basic health services, to
receive high-quality, evidence-based care. In such settings,
we believe it is a moral imperative to attempt to close gaps
in health care within communities and that researchers
should actively seek to 'ratchet up' the standard of care
available to the most vulnerable members of soci-
ety[16,24]. The MDP and wider Mwanza research group
have attempted to link research and justice by investigat-
ing options for the introduction of cervical cancer screen-
ing and colposcopy at population-level in Mwanza and by
facilitating specialist training in genitourinary and HIV
medicine to consolidate local quality health care provi-
sion. Finally, a significant proportion of the MDP
Mwanza budget is already allocated to health service pro-
vision in order to establish and maintain an entirely new
community-based health service.
Despite an approach based on the Seven-Step Framework,
the realities of trial implementation in a complex
resource-poor setting meant that several key SoC elements
were implemented with only partial success, most impor-
tantly adequate provision of care for women found to be
HIV seropositive during the trial and STI treatment serv-
ices for male sexual partners. A recent review by the Glo-
bal Campaign for Microbicides (GCM), which mapped
SoC at microbicide trial sites in Benin, Ghana, Nigeria,
South Africa, Tanzania and Zimbabwe[12], found such
difficulties to be common across all African trial sites and
urged those funding, sponsoring and coordinating HIV
prevention research to continue striving to 'ratchet up'
local standards of care in communities hosting clinical tri-
als. Key recommendations of the review include the need
for a greater emphasis on partnership working with com-
munities and local health service providers (co-location,
skills sharing and capacity building); use of referrals as a
mechanism for care; identification and reduction of barri-
ers to accessing care; and greater communication and
information sharing within the HIV prevention research
field to highlight approaches that appear to work and
those that do not. The limited resources available for clin-
ical trials in developing countries mean that community
stakeholders, researchers and sponsors will continue to
face extremely difficult choices when attempting to recon-
cile the immediate needs of trial participants with the
potential for longer term benefit to the wider community.
Can community-level and individual SoC considerations
be reconciled in HIV prevention research? Deciding the
extent and limits of researchers' involvement in the man-
agement of complex medical problems and emergencies
arising in settings such as Mwanza is problematic. Our
obligation and duty of care to participants has been tested
by a number of specific case studies, which suggest that in
addition to developing and agreeing broad SoC guidelines
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and principles in any given developing country research
environment there will always be a need to make case-by-
case decisions. We suggest that by establishing effective,
open and trusting partnerships with local communities
and stakeholders, researchers will be better equipped to
make informed choices in difficult circumstances and to
take decisions that make sense in the specific context in
which they work. Whilst individual high-profile clinical
cases are important, it is vital that researchers monitor
trial participants' access to and uptake of routine, non-
emergency health services and consider operational
research to clarify potential barriers and constraints in
order to inform future research program implementation.
Conclusion
Participatory methodologies enabled effective partner-
ships between researchers, participant representatives and
community stakeholders to be developed in Mwanza,
Tanzania and facilitated local dialogue and consensus on
what constitutes a locally-appropriate standard of care in
Case study: Acute psychosis and multiple vitamin deficiencies secondary to alcoholismFigure 3
Case study: Acute psychosis and multiple vitamin deficiencies secondary to alcoholism.
Family members reported that a trial participant had been discharged from a local hospital following admission 
for cerebral malaria but that she remained unwell at home, was unable to re-attend the trial clinic and that they 
were concerned for her health. The participant was unable to return to hospital due to lack of money for 
transport and hospital fees.  
Senior site staff visited the participant at home (a) and found that she had in fact been admitted with acute 
psychosis and on examination, there was clinical evidence of pellagra (b, c) and Wernicke-Korsakoff syndrome, 
as a result of multiple vitamin deficiencies secondary to long-standing alcohol dependency.  
The project supplied a project vehicle to transport her from the community to hospital; provided funds for her 
emergency re-admission, located and procured appropriate medicines through the private sector for her 
immediate and on-going inpatient treatment. 
Was it appropriate to use project resources in this way given that this standard of clinical care would 
not have been available to non-trial participants? 
a c 
b 
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the context of a phase III vaginal microbicide trial in this
setting.
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